ArticleFrontiers in oncology2025
Apparent diffusion coefficient predicts MGMT status in adult-type diffuse gliomas and is correlated with Ki-67 proliferation index.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prediction of MGMT promoter methylation in glioblastoma and grade 4 astrocytoma using fluid-suppressed chemical exchange saturation transfer MRI and machine learning-based segmentation.Frontiers in oncology · 2026Article
- Utility of Ki-67 index combined with alpha-fetoprotein and lactate dehydrogenase in distinguishing mature from immature ovarian teratomas in children.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the predictive value of apparent diffusion coefficient (ADC) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and its correlation with Ki-67 proliferation index in adult-type diffuse glioma, stratified by isocitrate dehydrogenase (IDH) subtype. Methods: This retrospective study enrolled 94 patients with pathologically confirmed glioma (2017-2024). ADCmin, ADCmean, and relative ADC (rADC) values were derived from diffusion-weighted imaging (b=1000 s/mm²). MGMT methylation, IDH mutation, and Ki-67 index were assessed by Pyrosequencing and immunohistochemistry. Receiver operating curve analysis was performed to evaluate diagnostic performance, and Spearman correlation was used to link ADC with Ki-67 index. Results: MGMT-methylated gliomas exhibited significantly higher ADCmin (0.86 vs. 0.74 × 10 Conclusion: ADC values, particularly rADCmin, were identified as non-invasive biomarkers for MGMT methylation prediction in IDH-wild-type gliomas. An inverse correlation between ADC and Ki-67 index supported their utility for assessing tumor proliferation. Standardizing rADC would improve its clinical applicability across imaging platforms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.